Supplementary Files
Keywords
Severidad
Bronquiectasias
Inmunodeficiencia
Adultos
Abstract
Background: Common variable immunodeficiency (CVID) is the most common primary symptomatic humoral immunodeficiency in adults. Antibody deficiency entails higher susceptibility to sinopulmonary infections and bronchiectasis formation, which is related to increased mortality. Scales have been established to assess the degree of severity of bronchiectasis in order to predict outcomes such as mortality, exacerbations and hospitalizations.
Objective: To determine bronchiectasis severity in adult patients with common variable immunodeficiency using the Brief Symptom Inventory scale.
Method: Cross-sectional study in adult population diagnosed with common variable immunodeficiency and attended to at the Mexican Institute of Social Security National Medical Center Siglo XXI Specialty Hospital.
Results: Bronchiectasis severity according to the Brief Symptom Inventory was mild in 60% of patients and moderate in 40%. Statistically significant differences were found for body mass index, number of affected lobes and type of bronchiectasis (p < 0.001).
Conclusions: Using bronchiectasis severity scales in patients with common variable immunodeficiency is indispensable for clinical and therapeutic decision making; however, determining the most appropriate instrument to assess bronchiectasis severity in this population is necessary.
References
Fernández RD, Juri M, Paolini M, Malbran A. Inmunodeficiencia común variable epidemiología y manifestaciones clínicas en 69 pacientes. Medicina (Buenos Aires). 2013;73(4):315-323. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802013000400004
Saika B, Gupta S. Common variable inmunodeficiency. Indian J Pediatr. 2016;83(4):338-334. DOI: 10.1007/s12098-016-2038-x
Bonilla FA, Barlan I, Chapel H, Quinti I, Routes JM, Tang ML, et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59. DOI: 10.1016/j.jaip.2015.07.025
Nonas S. Pulmonary manifestations of primary immunodeficiency disorders. Immunol Allergy Clin N Am. 2015;35(4):753-766.
Verma N, Grimbacher B, Hurts JR. Lung disease in primary antibody deficiency. Lancet Respir Med. 2015;3(8):651-660. DOI: 10.1016/S2213-2600(15)00202-7
Ellis CH, Cowman S, Fernandes M, Wilson R, Loebinger MR. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED score: a 19-year cohort styudy. Eur Respir J. 2016;47(2):482-489. DOI: 10.1183/13993003.01312-2015
Kumar-Panigrahi M. Common variable immunodeficiency disorder-an uncommon cause for bronchiectasis. Lung India. 2014;31(4):394-396. DOI: 10.4103/0970-2113.142138
Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446-1462. DOI: 10.1183/09031936.00119114
San-Roman J, Dovasio F, Kreindel T, Kucharczyck M. Bronquiectasias. Arch Argent Pediatr. 2006;104(4):357-377.
Vendrell M, De-Gracía J, Olveira C, Martínez MA, Girón R, Máiz L, et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronconeumol. 2008;44(11):629-640.
Galindo-Pacheco LV, Amaya-Mejía AS, O’Farrill-Romanillos PM, Del-Rivero-Hernández LG, Segura-Méndez NH. Calidad de vida en adultos con inmunodeficiencia común variable y bronquiectasias. Rev Alerg Mex. 2013;60:123-128.
Mogica MM, García LS, Silva VR, Montaño VB, Cruz MA. Neumopatías en pacientes con inmunodeficiencias primarias en tratamiento con gammaglobulina intravenosa. Rev Alerg Mex. 2007;54(1):14-19.
Hernández-Ojeda M, Vivas-Rosales IJ, Mendoza-Reyna LD, Múzquiz-Zermeño D, Maciel-Fierro AE, Segura-Méndez NH, et al. Tipo y localización de bronquiectasias en una cohorte de adultos con inmunodeficiencia común variable. Rev Med Inst Mex Seguro Soc. 2017;55 Supl 4:S414-S418.
De La Rosa D, Martínez-García MA, Olveira C, Girón R, Máiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: impact of severity, exacerbations, chronic bronchial infection and COPD coexistence. Chron Respir Dis. 2016;pii:1479972316643698. DOI: 10.1177/1479972316643698
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index, an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-584. DOI: 10.1164/rccm.201309-1575OC
Hampson FA, Chandra A, Screaton NJ, Condliffe A, Exley AR, Barbar JL, et al. Respiratory disease in common variable immunodeficiency and other primary immunodeficiency disorders. Clinical Radiology. 2012;67(6):587-595. DOI: 10.1016/j.crad.2011.10.028
Maglione PJ, Overbey JR, Radigan L, Bagiella E, Cunningham RC. Pulmonary radiologic findings in CIDV: Clinical and immunological correlations. Ann Allergy Asthma Immunol. 2014;113(4):452-459. DOI: 10.1016/j.anai.2014.04.024
Minov J, Karadzinka-Bislimovska J, Vasilevska K, et al. Assessment of the non-cystic fibrosis bronchiectasis severity: the FACED score vs the Bronchiectasis Severity Index. Open Respir Med J. 2015;9:46-51. DOI: 10.2174/1874306401509010046
Rosales-Mayor E, Polverino E, Raguer L, Alcaraz V, Gabarrus A, Ranzani O, et al. Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. Plos One. 2017;12(4):e0175171. DOI: 10.1371/journal.pone.0175171
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2018 Revista Alergia México